Welcome to our dedicated page for Rallybio news (Ticker: RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio stock.
Rallybio Corporation (NASDAQ: RLYB) is a clinical-stage biotechnology company whose news flow centers on the development of therapies for severe and rare diseases. Company press releases and SEC filings highlight progress across its pipeline, with particular emphasis on RLYB116, a differentiated C5 inhibitor being evaluated in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study designed to demonstrate complete and sustained complement inhibition with favorable tolerability.
Investors following RLYB news can expect regular updates on clinical milestones for RLYB116, including cohort dosing, interim data, and the program’s initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS), two hematologic conditions with significant unmet need. Rallybio also issues news on its preclinical programs, such as RLYB332, a long-acting monoclonal anti-matriptase-2 antibody for diseases of iron overload, and on the ENPP1 inhibitor program REV102 for hypophosphatasia (HPP), which originated from a joint venture with Recursion Pharmaceuticals.
RLYB news releases frequently cover financial results, cash runway guidance, and portfolio decisions, including the discontinuation of the RLYB212 program for fetal and neonatal alloimmune thrombocytopenia (FNAIT) based on Phase 2 pharmacokinetic data. Corporate and transaction updates, such as the sale of Rallybio’s interest in REV102 to Recursion for equity, milestones, and potential royalties, as well as workforce and cost-structure changes, are also disclosed.
This news page aggregates these company-issued updates, earnings announcements, and material event disclosures, offering a centralized view of Rallybio’s clinical progress, strategic transactions, and capital position for those tracking RLYB stock and its rare disease pipeline.
FAQ
What is the current stock price of Rallybio (RLYB)?
What is the market cap of Rallybio (RLYB)?
